English
|
简体中文
|
繁體中文
|
한국어
|
日本語
Home
|
About us
|
Services
|
Partners
|
Events
|
Contact us
|
Login
Sunday, December 21, 2025
Press Releases for Monday, December 15, 2025
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
22:00 HKT/SGT
GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes
21:09 HKT/SGT
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
21:00 HKT/SGT
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
21:00 HKT/SGT
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
18:41 HKT/SGT
希迪智駕招股進行中:構築智能駕駛產業化底座 多場景落地打開成長空間
18:06 HKT/SGT
希迪智驾招股进行中:构筑智能驾驶产业化底座 多场景落地打开成长空间
18:06 HKT/SGT
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
18:04 HKT/SGT
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
16:59 HKT/SGT
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份
16:59 HKT/SGT
云顶新耀发布2030战略规划 管理层及主要股东增持超3800万港元股份
16:59 HKT/SGT
Indonesia's KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge
13:00 HKT/SGT
国资护航+技术壁垒+优质保荐 华芢生物(02396.HK)PDGF管线直指18A赛道确定性价值
11:05 HKT/SGT
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
09:51 HKT/SGT
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值
09:28 HKT/SGT
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
07:30 HKT/SGT
ACN Search:
TANAKA's "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming at https://lnk.to/DLTA-8504
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home
|
About us
|
Services
|
Partners
|
Events
|
Login
|
Contact us
|
Cookies Policy
|
Privacy Policy
|
Disclaimer
|
Terms of Use
|
RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575